Cargando…
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
Lung adenocarcinoma is the most common subtype of lung cancer today. With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapy, personalized medicine has become a reality for patients with lung adenocarcin...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243502/ https://www.ncbi.nlm.nih.gov/pubmed/25505733 http://dx.doi.org/10.3389/fonc.2014.00329 |